Adam R. Craig - 30 Jun 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
President and CEO, Director
Signature
Adam R. Craig
Issuer symbol
N/A
Transactions as of
30 Jun 2022
Net transactions value
-$361,509
Form type
4
Filing time
06 Jul 2022, 17:19:43 UTC
Previous filing
03 Jun 2022
Next filing
16 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Award $13,086 +6,183 +37% $2.12* 22,861 30 Jun 2022 Direct F1
transaction CTIC common stock Options Exercise $22,710 +27,000 +118% $0.8411* 49,861 01 Jul 2022 Direct
transaction CTIC common stock Sale $162,000 -27,000 -54% $6.00 22,861 01 Jul 2022 Direct F2
transaction CTIC common stock Options Exercise $22,710 +27,000 +118% $0.8411* 49,861 05 Jul 2022 Direct
transaction CTIC common stock Sale $162,000 -27,000 -54% $6.00 22,861 05 Jul 2022 Direct F2
transaction CTIC common stock Options Exercise $15,327 +18,223 +80% $0.8411* 41,084 06 Jul 2022 Direct
transaction CTIC common stock Sale $111,343 -18,223 -44% $6.11 22,861 06 Jul 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27,000 -2.2% $0.000000 1,200,777 01 Jul 2022 Common Stock 27,000 $0.8411 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27,000 -2.2% $0.000000 1,173,777 05 Jul 2022 Common Stock 27,000 $0.8411 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -18,223 -1.6% $0.000000 1,155,554 06 Jul 2022 Common Stock 18,223 $0.8411 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
F2 This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
F3 One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.